MIRUM PHARMACEUTICALS INC (MIRM) Stock Fundamental Analysis
USA - NASDAQ:MIRM - US6047491013 - Common Stock
67.72 USD
-2.37 (-3.38%)
67.72 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to MIRM. MIRM was compared to 534 industry peers in the Biotechnology industry. The financial health of MIRM is average, but there are quite some concerns on its profitability. MIRM shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
MIRM had negative earnings in the past year.
In the past year MIRM had a positive cash flow from operations.
MIRM had negative earnings in each of the past 5 years.
MIRM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
MIRM has a better Return On Assets (-8.07%) than 84.83% of its industry peers.
MIRM has a better Return On Equity (-22.95%) than 82.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.07% | ||
| ROE | -22.95% | ||
| ROIC | N/A |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MIRM has a better Gross Margin (79.02%) than 84.46% of its industry peers.
In the last couple of years the Gross Margin of MIRM has declined.
The Profit Margin and Operating Margin are not available for MIRM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MIRM does not have a ROIC to compare to the WACC, probably because it is not profitable.
MIRM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MIRM has been increased compared to 5 years ago.
MIRM has a better debt/assets ratio than last year.
2.2 Solvency
MIRM has an Altman-Z score of 4.05. This indicates that MIRM is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.05, MIRM is doing good in the industry, outperforming 72.28% of the companies in the same industry.
A Debt/Equity ratio of 1.21 is on the high side and indicates that MIRM has dependencies on debt financing.
MIRM has a worse Debt to Equity ratio (1.21) than 78.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.05 |
ROIC/WACCN/A
WACC8.46%
2.3 Liquidity
MIRM has a Current Ratio of 3.13. This indicates that MIRM is financially healthy and has no problem in meeting its short term obligations.
MIRM has a worse Current ratio (3.13) than 62.73% of its industry peers.
A Quick Ratio of 2.97 indicates that MIRM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.97, MIRM is not doing good in the industry: 62.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.13 | ||
| Quick Ratio | 2.97 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 57.43% over the past year.
MIRM shows a strong growth in Revenue. In the last year, the Revenue has grown by 80.76%.
Measured over the past years, MIRM shows a very strong growth in Revenue. The Revenue has been growing by 160.12% on average per year.
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
Revenue 1Y (TTM)80.76%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
3.2 Future
MIRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.85% yearly.
MIRM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.49% yearly.
EPS Next Y62.39%
EPS Next 2Y41.69%
EPS Next 3Y39%
EPS Next 5Y30.85%
Revenue Next Year51.23%
Revenue Next 2Y34.62%
Revenue Next 3Y29.17%
Revenue Next 5Y24.49%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
MIRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
MIRM is valuated quite expensively with a Price/Forward Earnings ratio of 4742.30.
Based on the Price/Forward Earnings ratio, MIRM is valued cheaply inside the industry as 86.70% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of MIRM to the average of the S&P500 Index (31.86), we can say MIRM is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4742.3 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as MIRM's earnings are expected to grow with 39.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.69%
EPS Next 3Y39%
5. Dividend
5.1 Amount
MIRM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
67.72
-2.37 (-3.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.48%
Inst Owner Change-0.28%
Ins Owners1.88%
Ins Owner Change0.34%
Market Cap3.40B
Revenue(TTM)336.89M
Net Income(TTM)-58563000
Analysts85.88
Price Target83.64 (23.51%)
Short Float %17.48%
Short Ratio10.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.33%
Min EPS beat(2)10.69%
Max EPS beat(2)63.96%
EPS beat(4)3
Avg EPS beat(4)2.44%
Min EPS beat(4)-99.42%
Max EPS beat(4)63.96%
EPS beat(8)4
Avg EPS beat(8)-20.49%
EPS beat(12)7
Avg EPS beat(12)-22.94%
EPS beat(16)10
Avg EPS beat(16)-49.5%
Revenue beat(2)2
Avg Revenue beat(2)13.5%
Min Revenue beat(2)11.17%
Max Revenue beat(2)15.82%
Revenue beat(4)4
Avg Revenue beat(4)8.98%
Min Revenue beat(4)0.89%
Max Revenue beat(4)15.82%
Revenue beat(8)7
Avg Revenue beat(8)6.96%
Revenue beat(12)10
Avg Revenue beat(12)7.02%
Revenue beat(16)13
Avg Revenue beat(16)33.62%
PT rev (1m)2.64%
PT rev (3m)16.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)39.53%
EPS NY rev (1m)3.97%
EPS NY rev (3m)38.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)15.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.74%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4742.3 | ||
| P/S | 7.93 | ||
| P/FCF | N/A | ||
| P/OCF | 378.24 | ||
| P/B | 13.33 | ||
| P/tB | 196.8 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.86
EYN/A
EPS(NY)0.01
Fwd EY0.02%
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)0.18
OCFY0.26%
SpS8.54
BVpS5.08
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.07% | ||
| ROE | -22.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.02% | ||
| FCFM | N/A |
ROA(3y)-25.61%
ROA(5y)-29.64%
ROE(3y)-66.74%
ROE(5y)-66.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.6%
GM growth 5YN/A
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 42.81% | ||
| Cap/Sales | 2.42% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.13 | ||
| Quick Ratio | 2.97 | ||
| Altman-Z | 4.05 |
F-Score6
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)94.39%
Cap/Depr(5y)705.48%
Cap/Sales(3y)5.79%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%116.67%
EPS Next Y62.39%
EPS Next 2Y41.69%
EPS Next 3Y39%
EPS Next 5Y30.85%
Revenue 1Y (TTM)80.76%
Revenue growth 3Y160.12%
Revenue growth 5YN/A
Sales Q2Q%47.17%
Revenue Next Year51.23%
Revenue Next 2Y34.62%
Revenue Next 3Y29.17%
Revenue Next 5Y24.49%
EBIT growth 1Y47.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.43%
EBIT Next 3Y45.06%
EBIT Next 5YN/A
FCF growth 1Y98.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y109.33%
OCF growth 3YN/A
OCF growth 5YN/A
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What is the fundamental rating for MIRM stock?
ChartMill assigns a fundamental rating of 4 / 10 to MIRM.
What is the valuation status of MIRUM PHARMACEUTICALS INC (MIRM) stock?
ChartMill assigns a valuation rating of 2 / 10 to MIRUM PHARMACEUTICALS INC (MIRM). This can be considered as Overvalued.
Can you provide the profitability details for MIRUM PHARMACEUTICALS INC?
MIRUM PHARMACEUTICALS INC (MIRM) has a profitability rating of 3 / 10.